{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T02:35:02Z","timestamp":1770345302110,"version":"3.49.0"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,16]],"date-time":"2022-12-16T00:00:00Z","timestamp":1671148800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.ejca.2022.12.006","type":"journal-article","created":{"date-parts":[[2022,12,19]],"date-time":"2022-12-19T20:14:20Z","timestamp":1671480860000},"page":"198-207","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["A randomised, double-blind, dose-finding, phase II multicentre study of ODX in the treatment of patients with castration-resistant prostate cancer and skeletal metastases"],"prefix":"10.1016","volume":"181","author":[{"given":"Camilla","family":"Thellenberg-Karlsson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Egils","family":"Vjaters","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marju","family":"Kase","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teuvo","family":"Tammela","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristiina","family":"Ojamaa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ulf","family":"Norming","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claes","family":"Nyman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sven-Olof","family":"Andersson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oleg","family":"Hublarovs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcela","family":"Marquez-Holmberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enrique","family":"Castellanos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anders","family":"Ullen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anders","family":"Holmberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sten","family":"Nilsson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.ejca.2022.12.006_bib1","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.eururo.2013.10.055","article-title":"Visceral disease in castration-resistant prostate cancer","volume":"65","author":"Pezaro","year":"2014","journal-title":"Eur Urol"},{"issue":"15","key":"10.1016\/j.ejca.2022.12.006_bib2","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1056\/NEJMoa040720","article-title":"Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer","volume":"351","author":"Tannock","year":"2004","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.ejca.2022.12.006_bib3","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1056\/NEJMra030831","article-title":"Mechanisms of bone metastasis","volume":"350","author":"Roodman","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2022.12.006_bib4","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1023\/A:1006106209527","article-title":"Mechanisms, hypotheses and questions regarding prostate cancer micrometastases to bone","volume":"17","author":"Lange","year":"1999","journal-title":"Cancer Metastasis Rev"},{"key":"10.1016\/j.ejca.2022.12.006_bib5","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1146\/annurev-med-051517-011947","article-title":"Treatment of advanced prostate cancer","volume":"70","author":"Teo","year":"2019","journal-title":"Annu Rev Med"},{"issue":"9768","key":"10.1016\/j.ejca.2022.12.006_bib6","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S0140-6736(10)62344-6","article-title":"Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study","volume":"377","author":"Fizazi","year":"2011","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.ejca.2022.12.006_bib7","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1200\/JCO.2008.19.2146","article-title":"Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates","volume":"27","author":"Fizazi","year":"2009","journal-title":"J Clin Oncol"},{"issue":"15_Suppl May 20","key":"10.1016\/j.ejca.2022.12.006_bib8","doi-asserted-by":"crossref","first-page":"5002","DOI":"10.1200\/JCO.2021.39.15_suppl.5002","article-title":"Decreased fracture rate by mandating bone protecting agents in the EORTC 1333\/PEACEIII trial combining Ra223 with enzalutamide versus enzalutamide alone: an updated safety analysis","volume":"39","author":"Gillessen","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2022.12.006_bib9","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ejca.2020.08.019","article-title":"A randomised trial of 4- versus 12-weekly administration of bone-targeted agents in patients with bone metastases from breast or castration-resistant prostate cancer","volume":"142","author":"Clemons","year":"2021","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2022.12.006_bib10","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.ejca.2021.06.005","article-title":"Real-world incidence of symptomatic skeletal events and bone-modifying agent use in castration-resistant prostate cancer - an Australian multi-centre observational study","volume":"157","author":"Anton","year":"2021","journal-title":"Eur J Cancer"},{"issue":"3","key":"10.1016\/j.ejca.2022.12.006_bib11","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1213755","article-title":"Alpha emitter radium-223 and survival in metastatic prostate cancer","volume":"369","author":"Parker","year":"2013","journal-title":"N Engl J Med"},{"issue":"2\u20133","key":"10.1016\/j.ejca.2022.12.006_bib12","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/s10555-014-9494-4","article-title":"Integrating new discoveries into the \"vicious cycle\" paradigm of prostate to bone metastases","volume":"33","author":"Cook","year":"2014","journal-title":"Cancer Metastasis Rev"},{"issue":"3","key":"10.1016\/j.ejca.2022.12.006_bib13","doi-asserted-by":"crossref","first-page":"563","DOI":"10.3892\/ijo_00000705","article-title":"Development of a novel poly bisphosphonate conjugate for treatment of skeletal metastasis and osteoporosis","volume":"37","author":"Holmberg","year":"2010","journal-title":"Int J Oncol"},{"issue":"12","key":"10.1016\/j.ejca.2022.12.006_bib14","doi-asserted-by":"crossref","first-page":"6499","DOI":"10.21873\/anticanres.11249","article-title":"Bone-targeted novel cytotoxic polybisphosphonate conjugate in castration-resistant prostate cancer: a multicenter phase 1 study","volume":"36","author":"Thellenberg-Karlsson","year":"2016","journal-title":"Anticancer Res"},{"issue":"7","key":"10.1016\/j.ejca.2022.12.006_bib15","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/S1470-2045(07)70147-X","article-title":"Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study","volume":"8","author":"Nilsson","year":"2007","journal-title":"Lancet Oncol"},{"issue":"12","key":"10.1016\/j.ejca.2022.12.006_bib16","doi-asserted-by":"crossref","first-page":"4451","DOI":"10.1158\/1078-0432.CCR-04-2244","article-title":"First clinical experience with alpha-emitting radium-223 in the treatment of skeletal metastases","volume":"11","author":"Nilsson","year":"2005","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.ejca.2022.12.006_bib17","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s13550-016-0173-z","article-title":"Automated Bone Scan Index as a quantitative imaging biomarker in metastatic castration-resistant prostate cancer patients being treated with enzalutamide","volume":"6","author":"Anand","year":"2016","journal-title":"EJNMMI Res"},{"issue":"5","key":"10.1016\/j.ejca.2022.12.006_bib18","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1200\/JCO.2011.36.5791","article-title":"Bone scan index: a quantitative treatment response biomarker for castration-resistant metastatic prostate cancer","volume":"30","author":"Dennis","year":"2012","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2022.12.006_bib19","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1111\/j.1524-4733.2008.00409.x","article-title":"Estimating clinically meaningful changes for the Functional Assessment of Cancer Therapy--Prostate: results from a clinical trial of patients with metastatic hormone-refractory prostate cancer","volume":"12","author":"Cella","year":"2009","journal-title":"Value Health"},{"issue":"3","key":"10.1016\/j.ejca.2022.12.006_bib20","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/0168-8510(90)90421-9","article-title":"EuroQol--a new facility for the measurement of health-related quality of life","volume":"16","author":"EuroQol","year":"1990","journal-title":"Health Pol"},{"issue":"7547","key":"10.1016\/j.ejca.2022.12.006_bib21","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/nature14347","article-title":"The evolutionary history of lethal metastatic prostate cancer","volume":"520","author":"Gundem","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.ejca.2022.12.006_bib22","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.ejca.2022.06.057","article-title":"Radium-223 for patients with metastatic castration-resistant prostate cancer with asymptomatic bone metastases progressing on first-line abiraterone acetate or enzalutamide: a single-arm phase II trial","volume":"173","author":"Carles","year":"2022","journal-title":"Eur J Cancer"},{"issue":"4","key":"10.1016\/j.ejca.2022.12.006_bib23","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.urolonc.2010.08.007","article-title":"Biochemical markers of bone turnover and clinical outcomes in men with prostate cancer","volume":"30","author":"Saad","year":"2012","journal-title":"Urol Oncol"},{"issue":"4","key":"10.1016\/j.ejca.2022.12.006_bib24","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1007\/s12325-017-0505-z","article-title":"Expert system for bone scan interpretation improves progression assessment in bone metastatic prostate cancer","volume":"34","author":"Haupt","year":"2017","journal-title":"Adv Ther"},{"issue":"11 Pt B","key":"10.1016\/j.ejca.2022.12.006_bib25","first-page":"E628","article-title":"Prediction of survival benefit using an automated bone scan index in patients with castration-resistant prostate cancer","volume":"110","author":"Mitsui","year":"2012","journal-title":"BJU Int"},{"issue":"4","key":"10.1016\/j.ejca.2022.12.006_bib26","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.clgc.2016.12.020","article-title":"Prognostic value of automated bone scan index in men with metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate","volume":"15","author":"Miyoshi","year":"2017","journal-title":"Clin Genitourin Cancer"},{"issue":"5","key":"10.1016\/j.ejca.2022.12.006_bib27","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/j.eururo.2016.07.033","article-title":"Subgroups of castration-resistant prostate cancer bone metastases defined through an inverse relationship between androgen receptor activity and immune response","volume":"71","author":"Ylitalo","year":"2017","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.ejca.2022.12.006_bib28","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19041223","article-title":"Bone cell activity in clinical prostate cancer bone metastasis and its inverse relation to tumor cell androgen receptor activity","volume":"19","author":"Nordstrand","year":"2018","journal-title":"Int J Mol Sci"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804922018081?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804922018081?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:41:10Z","timestamp":1760733670000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804922018081"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":28,"alternative-id":["S0959804922018081"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2022.12.006","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A randomised, double-blind, dose-finding, phase II multicentre study of ODX in the treatment of patients with castration-resistant prostate cancer and skeletal metastases","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2022.12.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}